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Abbreviations 
MAF  minor allele frequency 
GWAS genome-wide association study 
SNP single nucleotide polymorphism 
BBJ  the Biobank Japan 
SIAH2      seven in absentia homolog 2 
bp base-pair 
DNA deoxyribonucleic acid 
LD linkage disequilibrium 
OR odds ratio 
QC quality control 
FGFR2 fibroblast growth factor receptor 2 
pGL3A_Major/Minor pGL3 basic plasmid having Construct of region A (-2,151 and -
571) with major or minor allele of rs2018246. 
pGL3B_Major/Minor pGL3 promoter plasmid having Construct of region B(+10,063 
and +11,152) with major or minor allele of rs16862837. 
pGL3C_Major/Minor pGL3 promoter plasmid having Construct of region C(+13,956 
and 15,864) with major or minor allele of rs72008905 
pGL3B290_Major/Minor pGL3 promoter plasmid having 290 bp Construct of region B 
(+10,267 and +10,556) with major or minor allele of 
rs16862837. 
pGL3B60_Major/Minor pGL3 promoter plasmid having 60 bp Construct of region B 
(+10,413and +10,470) with major or minor allele of 
rs16862837. 
pGL3B290_Major/Minor_mutant pGL3 promoter plasmid having 290 bp Construct of region B 
(+10,267 and +10,556) with mutant major or minor allele of 
rs1533711. 
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Abstract 
To identify genetic variants associated with the disease susceptibility, I performed a genome-
wide association study (GWAS) using a total of 1086 Japanese female patients with 
hormonal receptor-positive (HRP) breast cancer and 1816 female controls. I selected 33 
single-nucleotide polymorphisms (SNPs) with suggestive associations in GWAS (P-value 
less than 1 ×10
-4
) as well as 4 SNPs that were previously implicated their association with 
breast cancer for further replication by an independent set of 1653 cases and 2797 controls. I 
identiﬁed signiﬁcant association of the disease with a SNP rs6788895 (Pcombined= 9.43×10
-8 
with odds ratio (OR) = 1.22) in the SIAH2 (seven in absentia homolog 2) gene on 
chromosome 3q25.1. In addition, a SNP rs3750817 in intron 2 of the FGFR2 (ﬁbroblast 
growth factor receptor 2) gene, which was reported to be associated with breast cancer 
susceptibility, was signiﬁcantly replicated (Pcombined = 8.47×10
-8
 with OR =1.22). To identify 
functional variations of the SIAH2 gene, among the SNPs showing strong LD with 
rs6788895. I focused on three SNPs, SNP X, SNP Y, and SNP Z that are located in the 
transcription factor binding sites. I prepared six kinds of reporter plasmids carrying either 
major or minor allele of each SNP. Subsequent reporter gene assay disclosed that the minor 
non-susceptible T allele of SNP Y enhanced the reporter activity of SIAH2, suggesting that 
this variant might affect the expression or induction of SIAH2.  
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Chapter1 Introduction / Background 
Identification of genetic loci/genes associated with common diseases 
Variations in the human genome are associated with phenotypes and characteristics of 
individuals including color of skin and hair, height, blood type, the sensitivity of diseases, 
and response to drugs. Therefore, these variations have been used for the identification of 
responsible genes of hereditary diseases and genes associated with common diseases and 
adverse effect of drugs. Among the variations, single nucleotide polymorphism or SNP is a 
DNA sequence variation occurring when a single nucleotide- A, T, C, or G - in the genome 
differs between the individual. Within a population, almost all SNPs have only two alleles; 
the less common variant is termed a minor allele, while the more common variant is termed a 
major allele. Minor allele frequency (MAF) is the frequency carrying a minor allele in the 
population, and the MAF of each SNP is different among ethnic groups. SNPs are localized 
within coding or non-coding regions in exons, introns, 5`- or 3`-flanking regions of genes, or 
intergenic regions. Among the SNPs allocated incoding regions, those that do not change the 
amino acid sequence of the predicted protein are termed synonymous SNPs, while those that 
change the sequence are termed non-synonymous SNPs. In addition, SNPs located out of 
protein coding regions may affect gene splicing, transcription factor binding, or the sequence 
of non-coding RNA. 
Genome-wide association studies (GWAS) have been applied for the identification of 
loci/genes involved in common diseases and response to treatment, and loci/genes 
associated with adverse effect of drugs. In this method, the frequencies of SNPs across the 
genome are compared between individuals with a particular phenotype and those without 
the phenotype. The advancement of typing technologies enabled to investigate thousands of 
SNPs at the same time. This approach has successfully identified SNPs related to several 
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complex conditions
1
 such as diabetes
2-4
, heart abnormalities
5-7
, Parkinson disease
8, 9
, and 
Crohn’s disease10-12. Additionally, GWA studies have identified more than 200 
susceptibility loci associated with different types of human cancer
13
. The SNPs identified by 
GWAS may be applicable for the prediction and prevention of human diseases, and used for 
the identification of biomarkers of drug efficacy and adverse effect. 
The Biobank Japan Project 
The Biobank Japan (BBJ) project started as a leading project of Ministry of Education, 
Culture, Sports, Science and Technology, Japan in June 2003. This project was conducted by 
the collaboration of the Institute of Medical Sciences, the University of Tokyo, RIKEN, and 
66 collaborative hospitals. BBJ has successfully collected genomic DNA, serum, and clinical 
information of about 200,000 patients with different diseases. The collection covers 47 
human diseases including 10 cancers. The aim of this project include (1) discovery genes that 
susceptible to diseases and or drug response (pharmacogenomics), (2) identification of 
molecular targets for evidence based development of drugs or diagnostic tools, (3) 
identification of important genetic information that implemented in the establishment of 
“Personalized Medicine”, and (4) studies on gene-environment interaction for prevention of 
diseases
14
. 
Breast cancer 
Breast cancer originates from the epithelial cells in mammary gland.The gland is made up of 
different tissues including lobules with tiny tube-like structures generating milk, ducts 
carrying the milk from the lobes to the nipple, blood and lymphatic vessels; blood and 
lymphatic vessels serving for the delivery of oxygen and nutrients to the cells and drainage of 
bicarbonates and wastes, and the lymphatic vessels connecting lymph nodes for immune 
systems and coping with infection
15
. Breast cancer comprises of two main types, non-
invasive types and invasive types, and rare types. Non-invasive types include ductal 
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carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS), while invasive types include 
invasive lobular and invasive ductal carcinoma. In addition, rare types include inflammatory 
breast cancer, medullary breast cancer, mucinous breast cancer, metaplastic breast cancer and 
papillary breast cancer. The treatment of patients with breast cancer is decided by multiple 
factors including stage and grade of the disease, and the presence or absence of receptor 
expression such as estrogen receptor, progesterone receptor and HER2/new receptor in cancer 
cells. “Triple negative” cancer indicates a tumor that do not express any of these three 
receptors
16
. 
Hormones including estrogen and progesterone have key roles both in the development and 
progression of the disease
17-18
. Nearly 70% of breast cancersare known to express estrogen 
and progesterone receptors and their growth is dependent of the hormones.  The exposures to 
higher level and/or for longer period of estrogen such as early menarche, late menopause, late 
age at first pregnancy, nulliparity, postmenopausal obesity and high serum estrogen level in 
postmenopausal women is considered to be risk factors for breast cancer
19-21
. Furthermore, 
progestin, synthetic progesterone, was shown to markedly increase the risk of breast cancer in 
postmenopausal women when this hormonal therapy was provided for 10 years
22
. In addition, 
genetic factors play an important role in the development of breast cancer. Although germ-
line mutations in BRCA1 and BRCA2, and rare variants in CHEK2 and ATM have been shown 
to be implicated in high and moderate risks to breast cancer, respectively, several as yet 
unidentified common susceptibility variants are associated with low to moderate risk of the 
tumor
23-25
. 
Clarification of the link between breast carcinogenesis and SNPs 
GWAS issued for the identification of loci or genes that are statistically associated with 
specific phenotypes such as the sensitivities to drugs and the risks to disease through 
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genotyping thousands of SNPs
26-27
. Although GWAS enables to find a list of SNPs that are 
statistically associated with a phenotype of interest, it will not provide any information about 
the biological processes that link the SNPs to the phenotype. One of the major challenges to 
post GWAS research is to find the functional or causative SNPs associated with the 
phenotype and the mechanism(s) underlying the process. To resolve the link between the 
marker SNP and cancer, I searched additional SNPs that are in perfect linkage disequilibrium 
with the marker SNP. However, the clarification of functional link between the SNPs and 
phenotype is a hard task, because all SNPs with complete LD are located in the introns or 
intergenic regions. I hypothesized that if a SNP alters the ability of binding to the 
transcription factor, the variation should result in the different expression of the gene
28
. To 
identify the loci/genes associated with hormone receptor positive (HRP) breast cancer, I 
carried out a GWAS and a replication study, and successfully identified SNPs that are 
significantly associated with the disease.  Among the SNPs, the most significantly associated 
SNP was located in the intron 1 of SIAH2. To resolve the link between the marker SNP and 
cancer, I searched additional SNPs that are in perfect linkage disequilibrium with the marker 
SNP. Among these SNPs, I focused on SNPs within or close to the transcription factor 
binding elements, and analyzed the effect of variants on transcriptional activity using reporter 
assay. 
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Chapter 2 Aims of my study  
In Japan, breast cancer is the most common cancer among women and its incidence has been 
doubled in both pre- and post-menopausal women in the last 20 years. The marked increase is 
caused by the increase of estrogen receptor-positive subgroup
29
. Surgical removal of breast 
cancer is the main therapeutic modality, but patients at advanced stages or those with 
recurrent diseases need chemotherapy and/or radiotherapy. Although patients at early stages 
are cured by operation with or without adjuvant chemotherapy, more than ten thousands of 
patients die of this disease. Endocrine therapy for HRP tumors is effective, but cancer cells 
often become resistant to the treatment. Additionally, only one third of HRP breast cancer 
patients with metastatic disease respond to radiotherapy
30. Importantly, nearly half of patients 
with HRP tumor at an advanced stage suffer from recurrence
31-33. Therefore, novel 
therapeutic drugs and/or strategies are needed. The aim of this study is to identify the genetic 
factors susceptible to HRP breast cancer in the Japanese population and facilitate the 
development of novel approaches to prevent and/or treat this type of cancer. 
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Chapter 3 Materials and Methods 
Case and control subjects 
BBJ project and the GWAS analysis were approved by the Human Genome Research Ethics 
Committee in the Institute of Medical Science, The University of Tokyo (IMSUT-IRB, 15-3-
0627) and Ethical Committeein the Center for Genomic Medicine of RIKEN. All 
participating subjects provided written informed consent to the study. Characteristics of study 
subjects are shown in Table 1. Most of the breast cancer cases and all the controls in this 
study were registered in BBJ and stored at the Institute of Medical Science, The University of 
Tokyo. All cases were diagnosed to have a HRP breast cancer by immunohistochemistry with 
estrogen receptor and progesterone receptor-specific antibodies using breast tissue obtained 
in clinical examination (biopsy or cytology). 
In the initial GWAS, 1086 subjects with HRP breast cancer had been selected as cases; 846 
samples were obtained from BBJ and the remaining 240 samples were collected from 
collaborative hospitals; Tokushima Breast Care Clinic, Yamakawa Breast Clinic, Shikoku 
Cancer Center, and Itoh Surgery and Breast Clinic, Kansai Rosai Hospital, Sapporo Breast 
Surgical Clinic and Sapporo Medical University Hospital.Controls were 1816 female subjects 
including 231 healthy volunteers from the Midosuji Rotary Club, Osaka, Japan,and 1585 
subjects registered in BBJ as subjects with different eight non-cancerous diseases (hepatitis 
B, keloid, drug eruption, pulmonary tuberculosis, peripheral artery disease, arrhythmias, 
stroke, myocardial infarction) because they will not affect hormonal disturbance. In the 
replication study, we analyzed a total of 1652 cases including 1547 from BBJ and 105 from 
the collaborative hospitals. A total of 2797 female subjects registered in BBJ for other 
diseases (rheumatoid arthritis, amyotrophic lateral sclerosis, and liver cirrhosis) were used as 
controls. 
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Table 1. Characterization of subjects used in HRP breast cancer 
 
GWAS Replication 
C
a
se
 
Number of subjects 1,086 1,653 
Mean age(±SD) 66.7 (18.5) 60.7 (9.3) 
Mean age of menarche 12.4 12.2 
Mean age of menopause 48.3 47.9 
cases with DCIS* 52 207 
cases with Invasion  1,034 1,446 
Body weight index 
  
Platform 
Illumina HumanHap 
610K 
invader assay 
Source BioBank Japan  BioBank Japan 
  collaborative hospitals
2
 collaborative hospitals
1
 
 
 
  
 
 
  
C
o
n
tr
o
l 
Number of subjects 1,816 2,797 
Mean age(±SD) 61.3 (12.6) 65.9 (13.2) 
platform 
Illumina HumanHap 
610K 
Illumina HumanHap 610K 
Source BioBank Japan  BioBank Japan 
 Diseases in control
2
 MRC healthy  volunteer Rheumatoid arthritis 
 
  Hepatitis B Amyotrophic lateral sclerosis 
 
  keloid Liver cirrhosis 
 
  Drug eruption   
 
   Pulmonary tuberculosis   
 
  Peripheral artery disease   
 
  Arrhythmias   
 
   Stroke   
 
   Myocardial infarction   
1
 Tokushima Breast Care Clinic, Yamakawa Breast Clinic, Shikoku Cancer Center, and 
Itoh Surgery and Breast Clinic, Kansai Rosai Hospital, Sapporo Breast Surgical Clinic 
and Sapporo Medical University Hospital. 
2 
The control groups from BioBank Japan consisted of female individuals without cancer 
also without any disease related to breast cancer. 
*DCIS: Ductal carcinoma in situ 
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2266 cases with HRP breast cancer and 497 female controls with fourdifferent diseases 
(hepatitis B, keloid, drug eruption or pulmonary tuberculosis) from BBJ as well as 231 
healthy female volunteers from the Midosuji Rotary Club, Osaka, Japan were used for re-
sequencing analysis.  
 
Sample quality control 
In order to detect population stratification in this GWAS, Eigenstrat analysis was performed, 
which is based on principal component analysis (PCA) that detect the ancestry differences 
between cases and controls along continuous axes of variation
34
.  
 
SNP genotyping  
Illumina HumanHap 610 Genotyping Bead Chip (Illumina, San Diego, CA, USA) was used 
for the first stage genotyping. As a SNP quality control standard, p-value of Hardy-Weinberg 
equilibrium test should be <1.0 x 10
-6
 in controls, and call rate of ≥ 0.99 in both cases and 
controls was applied. SNPs with minor allele frequency (MAF) of <0.01 in both case and 
control samples were excluded further analysis. A total of 453,627 SNPs on autosomal 
chromosomes and 10,525 SNPs on X chromosome passed the quality control filters and were 
further analyzed. Illumina HumanHap 610 Bead Chip was also used for control samples in 
the replication study. All cluster plots were checked by visual inspection by trained 
personnel, and SNPs with ambiguous calls were excluded.  
I used the multiplex PCR-based Invader assay (Third Wave Technologies, Madison, WI, 
USA) for the genotyping of HRP breast cancer cases in the replication study. I designed all 
the primers within the Tm ranged from 55
o
C to 60
o
C as shown in Table2. The multiplex-PCR 
amplification was carried out using 15 ng of genomic DNA. Each total reaction volume is 
50l, consisting of PCR buffer, dNTP, 50 pmol of each primer and 10 unit of HotStart. 
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Table 2. Primer sequences and probes used in invader assay for the SNPs identified by GWAS. 
SNP Sequence ID Sequence 
rs708766 rs708766_F GGGTGGGTTAAAGCCTTCTC 
 
rs708766_R GCCCAGAGTCCAGTGGTATC 
 
rs708766_INV CCCTGGAACCCACATCCACCCTGAT 
 
rs708766_VIC CGCGCCGAGGATATTGCTGGAGGTACTC  
 
rs708766_FAM ATGACGTGGCAGACCTATTGCTGGAGGTACT  
   
rs53915 rs53915_F TACGTTTACAGGCCTCTGCT 
 
rs53915_R CTCATTACAGCCATCGAACC 
 
rs53915_INV CCTTTAGAGAGGTTACAAAGGGAGGGAGACTGGTA 
 
rs53915_VIC CGCGCCGAGGTTCAAATCACTGGAATCCAGAG 
 
rs53915_FAM ATGACGTGGCAGACCTCAAATCACTGGAATCCAGA  
   
rs1012357 rs1012357_F TTTTACATTTGGCTCAGTGCTC 
 
rs1012357_R TGAAAAATCATCTGCTTTTGAGTC 
 
rs1012357_INV GAAATAGTAAAAAAACAAAAAACTA 
 
rs1012357_VIC CGCGCCGAGGGAAGTATCATATCTCCA 
 
rs1012357_FAM ATGACGTGGCAGACAAAGTATCATATCTCCAT 
   
rs560737 rs560737_F GGGCGCAATAACTATTTCTGA 
 
rs560737_R CTAAATTCCCTGGGTCCTTTG 
 
rs560737_INV CCTTTAGAGAGGTTACAAAGGGAGGGAGACTGGTA 
 
rs560737_VIC CGCGCCGAGGTTCAAATCACTGGAATCCAGAG 
 
rs560737_FAM ATGACGTGGCAGACCTCAAATCACTGGAATCCAGA  
   
rs6788895 rs6788895_F TGGTCCAAGGTAAACTCCAC 
14 
 
 
rs6788895_R TCATTCAGTGGTCTTTGTGG 
 
rs6788895_INV TTGGGAGGTGAACCTGGAAGTGGGAAGAAGAGATATAA  
 
rs6788895_VIC CGCGCCGAGGTGAGCTCAACTGGAAGG 
 
rs6788895_FAM ATGACGTGGCAGACGGAGCTCAACTGGAAG 
   
rs9835984 rs9835984_F AAAGTGGGTTCATCCATTGC 
 
rs9835984_R ACACCTGGCCCTGAGTTCTA 
 
rs9835984_INV CTCACTGTACTTACTGCTCAATTTTTCTGTAAACCTAAAGTGCTCTAAAAT 
 
rs9835984_VIC CGCGCCGAGGATAAAGACTATTAACAAACAGCAAC 
 
rs9835984_FAM ATGACGTGGCAGACGTAAAGACTATTAACAAACAGCAA 
   
rs10017875 rs10017875_F TTGTCTTCCTGAATATCTCCTCCT 
 
rs10017875_R CCAGAATGTTGGCTATGTATCAC 
 
rs10017875_INV CCTCCTTCCACACACACTTCTTTCATCG 
 
rs10017875_VIC CGCGCCGAGGACTGATGATTTTTCTTTCA 
 
rs10017875_FAM ATGACGTGGCAGACGCTGATGATTTTTCTTTC 
   
rs6844819 rs6844819_F CATGTCTTGATGTTCGTTTGG 
 
rs6844819_R TCTCTCAACAGTCGTCATCTTCA 
 
rs6844819_INV CAATTTGTTACTTTTGTCACTATTTCAG 
 
rs6844819_VIC CGCGCCGAGGATGTTTACAGGACTTCGT 
 
rs6844819_FAM ATGACGTGGCAGACGTGTTTACAGGACTTCG 
   
rs4921443 rs4921443_F AACCTGCTTGAAATTCCCCTA 
 
rs4921443_R AGGTCTCCAATGTGCATACTCTT 
 
rs4921443_INV GTCTTTGCAATAATTCAAAGGCAGTATA 
 
rs4921443_VIC CGCGCCGAGGGCTTTAGTGGTTAAGAGT 
 
rs4921443_FAM ATGACGTGGCAGACACTTTAGTGGTTAAGAGTG 
15 
 
   
rs10039851 rs10039851_F GGGAATACTTCTGAACTCAC 
 
rs10039851_R TTTATAAGTTTTTACAGATT 
 
rs10039851_INV GACAAAGGCATTATAAGAAAATAAAAT 
 
rs10039851_VIC CGCGCCGAGGCGGCAGACCAATATCTCT 
 
rs10039851_FAM ATGACGTGGCAGACTGGCAGACCAATATCTCTC 
   
rs2278386 rs2278386_F CCAACCTCTCATGTGCCAAT 
 
rs2278386_R TCCCTATTGTACCAGGCATTC 
 
rs2278386_INV GTTGTTCTGGTTTAATGATAATCAAATGAGGTCCACAGACCCT 
 
rs2278386_VIC CGCGCCGAGGATGCCAGTTAGCAAACTG  
 
rs2278386_FAM ATGACGTGGCAGACGTGCCAGTTAGCAAACT  
   
rs9456909 rs9456909_F ATTTGACATTGGTGTCCTTGG 
 
rs9456909_R CTCAAATGCCTGCACACAATA 
 
rs9456909_INV AACAATATGTCCCAATTAATTCTG 
 
rs9456909_VIC CGCGCCGAGGATATTAATTGGGGGGGG 
 
rs9456909_FAM ATGACGTGGCAGACGTATTAATTGGGGGGG 
   
rs13199020 rs13199020_F AGAAGGAAAAAAGTCACCTC 
 
rs13199020_R GGCATGAGGATTGCTTGAAC 
 
rs13199020_INV ATAGTGGACTTGCCCTTAAAACCAGT 
 
rs13199020_VIC CGCGCCGAGGCATAAGCTGGAAGAGAATA 
 
rs13199020_FAM ATGACGTGGCAGACTATAAGCTGGAAGAGAAT 
   
rs6453815 rs6453815_F TCAAAGCATAGCACAGTATTTGG 
 
rs6453815_R ATGTGGAATGAGGTCCAAGA 
 
rs6453815_INV CAAGCTTCTTTCTCAAGCCCTATTTTGCCAACATAGTGTTTTGCT 
16 
 
 
rs6453815_VIC CGCGCCGAGGATATAGTAGGTGTCCAACTG  
 
rs6453815_FAM ATGACGTGGCAGACGTATAGTAGGTGTCCAACT  
   
rs10456973 rs10456973_F AGGCACCGTCCTCCAGTATT 
 
rs10456973_R TCAGAGTGAGGCAGATGGAA 
 
rs10456973_INV CTGGCTGGGGGTCCTCAGTATTTCCA 
 
rs10456973_VIC CGCGCCGAGGTGGAACACCTAACCCAC  
 
rs10456973_FAM ATGACGTGGCAGACCGGAACACCTAACCCA  
   
rs10250216 rs10250216_F CCAAAAATGGGGAATCACAG 
 
rs10250216_R GAGAGCACCTACCCCGTTCT 
 
rs10250216_inv GGAAAGGAGAGATTTGCCTACAAATTAGGCTGGAAACCT  
 
rs10250216_VIC CGCGCCGAGGATAGGGAAGAAATTGTTTGCG  
 
rs10250216_FAM ATGACGTGGCAGACGTAGGGAAGAAATTGTTTGC  
   
rs7814396 rs7814396_F CCATACCCTCCATTCTGTGTG 
 
rs7814396_R AGCCTTGTGGGGAATTAGAGA 
 
rs7814396_inv GAATCAGGCCTTATCATATCTCCCTGTA 
 
rs7814396_VIC CGCGCCGAGGAGTGTAGATACATTTACAT 
 
rs7814396_FAM ATGACGTGGCAGACACTGTAGATACATTTACA 
   
rs822304 rs822304_F TTCCAAACAAGCAAGAACTCAA 
 
rs822304_R TCATCTGCCTTCTTTCTTTCTCA 
 
rs822304_inv TATGGAAAGGAAGAGGCTATA 
 
rs822304_VIC CGCGCCGAGGGAGGCTACTCTTCAATCAT 
 
rs822304_FAM ATGACGTGGCAGACGAGGCTACTCTTCAATCA 
   
rs4741635 rs4741635_F CCAAAACACATTCAATGGAAGA 
17 
 
 
rs4741635_R TGCCAAGCTCCTTAGCATAAC 
 
rs4741635_inv TTCTGTTTTCCTTTTTGAAGCACTCTGTGTG 
 
rs4741635_VIC CGCGCCGAGGATTGTGTGGGAGAGTTATGCTA 
 
rs4741635_FAM ATGACGTGGCAGACGTTGTGTGGGAGAGTTATGCT 
   
rs6602097 rs6602097_F GCCTAAGGCTTCGGAGTTAAA 
 
rs6602097_R CCTTAGCCAAGGGGAGATGT 
 
rs6602097_inv TTCTTCATCTGTAAGAAAGGTGACTAAC 
 
rs6602097_VIC CGCGCCGAGGTACCTCATTAGAGTGTTG 
 
rs6602097_FAM ATGACGTGGCAGACCACCTCATTAGAGTGTT 
   
rs1028722 rs1028722_F AAAAGCCTAACCGAGTGCAG 
 
rs1028722_R CAAACATATGTGGGCCTGCT 
 
rs1028722_INV CGTATGGTCACTGCTAGAAATGTTTGCCACCCA 
 
rs1028722_VIC CGCGCCGAGGTGGTCTAACTACACGAGTAG  
 
rs1028722_FAM ATGACGTGGCAGACCGGTCTAACTACACGAGTA  
   
rs12591707 rs12591707_F CCAGACCGAAGACAAGAAGTTG 
 
rs12591707_R CCCAAATTTATTTATGCCAGTCA 
 
rs12591707_INV TTTAATTTTCAGAAACAACTGTATTTAC 
 
rs12591707_VIC CGCGCCGAGGTTTTCTTATTTGTATTTC 
 
rs12591707_FAM ATGACGTGGCAGACCTTTCTTATTTGTATTT 
   
rs11076442 rs11076442_F AAGTAATGACCGCCAACAAAA 
 
rs11076442_R TTCTGCAAAGGGTAGTCTCCA 
 
rs11076442_INV AACTGATTTTAGGTATAATGTGGGTCC 
 
rs11076442_VIC CGCGCCGAGGTGCTGCTTGTACTAATCGGT 
 
rs11076442_FAM ATGACGTGGCAGACCGCTGCTTGTACTAATCGG 
18 
 
   
rs4793427 rs4793427_F AGATTCTCCCACACAAATGGA 
 
rs4793427_R AGTATCATCGGGGGATAGAGC 
 
rs4793427_INV AAGCAGAAGAGGCCACTTGACATAC 
 
rs4793427_VIC CGCGCCGAGGTGTTTACTAAACACCCGCTCT 
 
rs4793427_FAM ATGACGTGGCAGACCGTTTACTAAACACCCGCTC 
   
rs7219201 rs7219201_F GTGCTGGGATTACAGGCATAA 
 
rs7219201_R AAAACTGTGTCGCAAAGGAGA 
 
rs7219201_INV TCTGGATGCTGCCCCTCATCAGATAC 
 
rs7219201_VIC CGCGCCGAGGTACAGTTTGCAGATATTT 
 
rs7219201_FAM ATGACGTGGCAGACCACAGTTTGCAGATATT 
   
rs871739 rs871739_F AGCAGTGAGGTTAGGGAGTCA 
 
rs871739_R AGACATCGAGGACAGATGGAG 
 
rs871739_INV TCTCATCCGCCCAGCAGGGAGTAGGCAC 
 
rs871739_VIC CGCGCCGAGGTGGGATCGCGGCCTGGGCA 
 
rs871739_FAM ATGACGTGGCAGACCGGGATCGCGGCCTGGGC 
   
rs6040836 rs6040836_F TTTACCCATCCCTCAGCTACC 
 
rs6040836_R TACCTAATGTCAGGGGCTGAA 
 
rs6040836_INV GGGCAGATAGGGAGGGAGGTAAGTC 
 
rs6040836_VIC CGCGCCGAGGAGGTAAGCAGGGTATTTAT 
 
rs6040836_FAM ATGACGTGGCAGACCGGTAAGCAGGGTATTTA 
   
rs6036227 rs6036227_F AAGTCAGTAACCAGCCCCTTG 
 
rs6036227_R CTCCAGAAGCCAGCAGAATTA 
 
rs6036227_INV AAGGCTGGTGATGCTTTACACCTT 
19 
 
 
rs6036227_VIC CGCGCCGAGGCGGGGTCCTTCAGAGAAAT 
 
rs6036227_FAM ATGACGTGGCAGACTGGGGTCCTTCAGAGAAA 
   
rs2853218 rs2853218_F GGACTGCTGGCAGAATCTAA 
 
rs2853218_R CCATTAGCCCTTCCATTTCT 
 
rs2853218_inv GTACAACAGAGCTTTTGCCAGCCAGTGTCCTGAAAAATA 
 
rs2853218_VIC CGCGCCGAGGTAGAGGGGCTGGCAAATTTA 
 
rs2853218_FAM ATGACGTGGCAGACCAGAGGGGCTGGCA 
   
rs8129581 rs8129581_F ATCAAATGTTCCCTTCACCA 
 
rs8129581_R CAAGGTGCTATGTGGCTTCT 
 
rs8129581_inv CGTGAAAACGGAGACATCATTTAAAATCATCACTGATAATTAAAATGGGAACAGAT 
 
rs8129581_VIC CGCGCCGAGGATTTAGAGATTTGGAGAATTCTC 
 
rs8129581_FAM ATGACGTGGCAGACGTTTAGAGATTTGGAGAATTCT 
   
rs17820958 rs17820958_F AGCAAGTTGTCCTGTGCTATGA 
 
rs17820958_R TGGTTCTGCTTTGTTTTAGGG 
 
rs17820958_inv TGAGGAGACAAGGCTAATGGGAAAG 
 
rs17820958_VIC CGCGCCGAGGAAGGCTGTTAGCCCTGCCC 
 
rs17820958_FAM ATGACGTGGCAGACGAGGCTGTTAGCCCTGCC 
   
rs5997921 rs5997921_F TCTCTCCACATCTCCACAACC 
 
rs5997921_R ATTTCTCTGAGCCATCCAGGT 
 
rs5997921_inv TCTGCCTAGAATGCCCCCTTACTCTG 
 
rs5997921_VIC CGCGCCGAGGTTTCACTTAACTCCTGCT 
 
rs5997921_FAM ATGACGTGGCAGACGTTCACTTAACTCCTGC 
   
rs1034587 rs1034587_F ACCCAGCCTAATCCCTGTTT 
20 
 
 
rs1034587_R ACCCTTGACTGCTCTTCCAG 
 
rs1034587_inv GTAAAGGAGGTTGCTGAGGAAAGCAAGGCGT  
 
rs1034587_VIC CGCGCCGAGGAGGAAGTTAAACTCAAAAGCC 
 
rs1034587_FAM ATGACGTGGCAGACCGGAAGTTAAACTCAAAAGC 
            F: Forward primer. 
            R: Reverse primer. 
            INV: Invader. 
            VIC-sequence: CGCGCCGAGG 
            FAM-sequence: ATGACGTGGCAGAC 
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DNA polymerase Promega, Madison, WI. The multiplex PCR condition was for initial 
denaturation 94
o
C for 2 min, followed by 35 cycles of denaturation at 94°C for 15 s, 
annealing at 60°C for 45s, and extension at 72°C for 2 min. The PCR products were diluted 
in 1:10 and transferred into plates (384 well). The products were air-dried overnight before 
Invader assay. Invader assay combines a universal fluorescent resonance energy transfer 
(FRET) system and structure-specific cleavage enzymes. FRET probes were labeled with 
FAM or VIC that corresponded to alleles. Signal intensity was calculated as the ratio of FAM 
or VIC to ROX, an internal reference. The dried PCR products were resolved in the reaction 
mixture of 3μl, containing 0.5μl of distilled water, 0.5μl of signal buffer, 0.5μl of structure-
specific cleavage enzyme, 1μl of allele-specific probe mix and 0.5μl of FRET probes. The 
reaction was carried out by the incubation of samples at 95°C for 5 minfollowed by 5min at 
63°C, and the genotype was analyzed by Applied Biosystems 7900 HT Fast Real-time PCR 
system. Additional incubation was done when the allele discrimination plot did not reveal 
distinct cluster of risk homozygote, heterozygote and non-risk homozygote. 
For the genotyping of additional 22 variations discovered by re-sequencing analysis, the 
multiplex PCR-based Invader assay was also applied (Table 3) 
Statistical analysis 
I tested the associations of SNPs by employing the Cochran–Armitage trend test for both the 
initial GWAS and replication analyses. For the combined study, the simple combined method 
was applied. In the replication analyses, significance level was applied to be P-value of <1.35 
x 10
-3
 (calculated as 0.05/37). Odds ratios (ORs) and confidence intervals were calculated 
using the non-susceptible allele as a reference. Heterogeneity between the initial GWAS and 
replication subjects was examined using the Breslow– Day test. The genomic inflation factor 
(lGC) was calculated from the median of the Cochran–Armitage trend test. 
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Table 3. Primer sequences and probes of the SNPsdiscovered by re-sequencing analysis 
SNP Sequence ID Sequence 
rs6788895 rs6788895_F TGGTCCAAGGTAAACTCCAC 
 
rs6788895_R TCATTCAGTGGTCTTTGTGG 
 
rs6788895_INV TTGGGAGGTGAACCTGGAAGTGGGAAGAAGAGATATAA 
 
rs6788895_VIC CGCGCCGAGGTGAGCTCAACTGGAAGG 
 
rs6788895_FAM ATGACGTGGCAGACGGAGCTCAACTGGAAG 
   
rs476663 rs476663_F GGAGGATGCTAGAAAACTACCTCA 
 
rs476663_R TTCACTTGTGAGGCATTACAGAA 
 
rs476663_INV GTAAAATGTACCTTACGGTAAACC 
 
rs476663_VIC CGCGCCGAGAAATAGTTGAAAAGAGGA 
 
rs476663_FAM ATGACGTGGCAGACCAATAGTTGAAAAGAGG 
   
rs7615292 rs7615292_F CCACTGCTGTTTTTGCTTCTC 
 
rs7615292_R GAGGCTGTCATCCTTGCTTC 
 
rs7615292_INV TATCACTAGCAACAAGCAGATG 
 
rs7615292_VIC CGCGCCGAGGAGTATGCACTATGTGACT 
 
rs7615292_FAM ATGACGTGGCAGACGGTATGCACTATGTGAC 
   
rs7636866 rs7636866_F CAAAAGACCACACCAAGAGGA 
 
rs7636866_R GGGGTCTAAGGCTGACACCTA 
 
rs7636866_INV TGTTAATTCCTAGATACCAGATGGAGA 
 
rs7636866_VIC CGCGCCGAGGTTCAGCCCACAAGTAGACACC 
 
rs7636866_FAM ATGACGTGGCAGACATCAGCCCACAAGTAGACAC 
   
rs2116684 rs2116684_F CTGCATATACCCTTGGGCTCT 
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rs2116684_R AATGGCCACATATTGCAGTTC 
 
rs2116684_INV AAAAAATCTCAGTAAGAAAAG 
 
rs2116684_VIC CGCGCCGAGGCAGAATTTAAATGACCAC 
 
rs2116684_FAM ATGACGTGGCAGACGAGAATTTAAATGACCA 
   
rs57359526 rs57359526_F GCAAGCTGTACAGGAAGCATA 
 
rs57359526_R TCCTCTTGGTGCTGTTCTCAT 
 
rs57359526_INV AGAAAGCTTCCAATCATGGTGGAAGG 
 
rs57359526_VIC CGCGCCGAGGTCAAAGGGGGAGTGAGGCAT 
 
rs57359526_FAM ATGACGTGGCAGACGCAAAGGGGGAGTGAGGCA 
   
rs6789306 rs6789306_F ATTACCCCACTGCATCCTTTT 
 
rs6789306_R GGGTCAGCAAGCTTTGAGAG 
 
rs6789306_INV CTGGTCAGTCTGGTTCTGGCCAGTA 
 
rs6789306_VIC CGCGCCGAGGGGAGGTTAACATGAGA 
 
rs6789306_FAM ATGACGTGGCAGACAGAGGTTAACATGAG 
   
rs1148369 rs1148369_F GAATCAGATCAGAGGCTGCAT 
 
rs1148369_R CCAAAGTGCTGGGATTACAAG 
 
rs1148369_INV CGCTTTGTCTGCAAGTGGTGGT 
 
rs1148369_VIC CGCGCCGAGGCTATACATGTGAAGTCA 
 
rs1148369_FAM ATGACGTGGCAGACTTATACATGTGAAGTC 
   
rs76182650 rs76182650_F CTCTACCACAGAACGGGAGAG 
 
rs76182650_R TCCACACATAACTGGCCAAAG 
 
rs76182650_INV CTTTCACTGATAACTATTTACTCT 
 
rs76182650_VIC CGCGCCGAGGCAGTTCCAGGTCATGGT 
 
rs76182650_FAM ATGACGTGGCAGACTAGTTCCAGGTCATGG 
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rs1833811 rs1833811_F TGGAGAACCAGTTTTGTGAGG 
 
rs1833811_R TGAGGGGAATAGAGCTGTTTG 
 
rs1833811_INV ATGCCAGGTTCCCACCTGCACAACCACA 
 
rs1833811_VIC CGCGCCGAGGGTAACTGCCCTGACAGTTC 
 
rs1833811_FAM ATGACGTGGCAGACATAACTGCCCTGACAGTT 
   
rs61628582 rs61628582_F AGGAAGCATAGTGGCTTCTGC 
 
rs61628582_R TCCTCTTGGTGCTGTTCTCAT 
 
rs61628582_INV GCAAGGGTGGGAGAGGTGCTTCACACTTC 
 
rs61628582_VIC CGCGCCGAGGTTTAAATAACCAGATCTCATA 
 
rs61628582_FAM ATGACGTGGCAGACCTTAAATAACCAGATCTCAT 
            F: Forward primer. 
            R: Reverse primer. 
            INV: Invader. 
            VIC-sequence: CGCGCCGAGG 
            FAM-sequence: ATGACGTGGCAGAC 
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The quantile–quantile plot of the logarithms of the genome-wide P-values was generated by 
the “snpMatrix” package in R program v2.10.0, and the Manhattan plot was generated using 
Haploview v4.1. Haplotype analysis was performed by the use of Haploview v4.1 by 
considering genotyped SNPs located within 500 kb upstream or downstream of the marker 
SNP. (Haploview software was used to analyze linkage disequilibrium (LD) values, visualize 
haplotype.) 
 
Genotype imputation 
The SNPs with low genotyping rate (<99%), showing deviations from Hardy-Weinberg 
equilibrium (>1.0 x 10
-6
), or MAF (<0.01) were excluded from the analysis. MACH version 
1.0 was used to estimate haplotypes, map crossover and error rates using 50 iterations of the 
Markov chain Monte Carlo algorithm. Imputation analysis was carried out by referring to the 
genotype data of Japanese (JPT) individuals as deposited in the Phase II HapMap database 
using MACH v1.0 Genotypes of SNPs that are located in the genomic region within 500 kb 
upstream or downstream of the marker SNP (the SNP that showed the strongest association 
with HRP breast cancer) were imputed. The imputed SNPs with an imputation quality score 
of r
2 
< 0.3 were excluded from the subsequent analysis. 
 
Re-sequencing analysis 
I explored additional SNPs in the genomic region of the SIAH2 (seven in absentia homolog 2) 
gene using DNA samples of 96 cases with HRP breast cancer. A total of 98 sets of primers 
were utilized (Table 4) to amplify the 22,353 bps (two exons, one intron, 5 UTR and 3UTR) 
of the genomic region corresponding to the SIAH2 gene. The sequence information was 
obtained from UCSC Genome Bioinformatics database (NM_005067). PCRs were performed 
using GeneAmp PCR system 9700 (Applied Biosystems, Foster City, CA, USA). The PCR  
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Table 4. Primer sequences for re-sequencing of SIAH2 
PrimerSequences position product size 
F1 CCTGAAGTTGCCTTTCTCGT Exon 1 362 
R1 CACCCGCTTCTGGAACAG 
  
F2 CAGCGGCTGTTCCAGAAG Exon 1 366 
R2 CTGCTTGCTGCAGGGTTTAT 
  
F3 AATAAACCCTGCAGCAAGCA Exon 1 223 
R3 AGTCAAAGCAGACCGGACAC 
  
F4 TCAGGAACCTGGCTATGGAG Intron 420 
R4 CTCCTCAATCCCCACACAGT 
  
F5 TGCAGACGTGTATTCGGGTA Intron 520 
R5 GGAGGGGAGAGATCTTGGTC 
  
F6 AAAATGCAAGCCACCAAGAC Intron 646 
R6 GGGCAGCAGACCAAATTAAA 
  
F7 GGCCATTTAAGCTGTCTTGC Intron 439 
R7 AGAAATCCTATGGGGCATCC 
  
F8 TGGTTGGAAAAGGTTTGGTG Intron 417 
R8 AAGGCTGAGAACCCCTGATT 
  
F9 CCCAAGAGAAAGGGAAGGAA Intron 403 
R9 AGCTGCCCTGCCAATAGTTT 
  
F10 GGCAGCTCAGCCAGTTAGTC Intron 476 
R10 AGCTGACCCCTGCAAAGTAA 
  
F11 TGCAGGGGTCAGCTTTTACT Intron 425 
R11 GCAGTCCAGAGCTGTGATGA 
  
F12 AAACCGTCTGGTTGGATGAG Intron 479 
R12 TTACAGACGTGAGCCACTGC 
  
F13 GGGAACCGGATGCATTATTA Intron 489 
R13 CCACCACACCTGGCTATTTT 
  
F14 AAAGTTAGCTGGGCATGGTG Intron 443 
R14 GGGCACAGGATGTCAAAAGT 
  
F15 GCAGTGAGCTGAGATTGTGC Intron 434 
R15 TCCAGCTGAGGCTTTCAAAT 
  
F16 GTGCCCAGACTTAAACTCACC Intron 556 
R16 GAGTAAAGGCTGCCTCTTGG 
  
F17 TCACCTCTGGCTGATTGGT Intron 528 
R17 GTTCCTGATGGCCAGAAAAT 
  
F18 TCCCAAGGTTCTTTCTTACCC Intron 497 
R18 AGCCCCGGAGTTAATGTATG 
  
F19 ATTAACTCCGGGGCTCAAG Intron 536 
R19 AACTCGCCAGCAATACACAG 
  
F20 TGGCCACATATTGCAGTTCT Intron 381 
R20 ATTAGCCAAGCCTGATGGTG 
  
F21 CTACTTGGGAGGCTGAGAGG Intron 545 
   R21 CAACCTTGAGGCTTGGAGAG 
  
F22 ATGCAAAGTGCCTGACACAG Intron 547 
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R22 GGGACATAGACCCAAACCAT 
  
F23 TGAGATGGTGATATGGTTTGG Intron 552 
R23 CTGCAATATGTGGCCATTAAA 
  
F24 TGGCCACATATTGCAGTTCT Intron 593 
R24 TGGGAAGAAATGGACATTCA 
  
F25 CAGTTGAATGTCCATTTCTTCC Intron 579 
R25 AGAGGTTGTAGTGAAAAAGACACTG 
  
F26 AACCTCTTGCTTTTTCTGTGC Intron 403 
R26 AGCCTGAAATGCCAGCTAAT 
  
F27 GGGGCCGGAGAAGAATAA Intron 462 
R27 AGCTCTATTCCCCTCAGCAG 
  
F28 ACTGCTGAGGGGAATAGAGC Intron 628 
R28 CCAAAAATCTGTCCTTTTTGC 
  
F29 GCAAAAAGGACAGATTTTTGG Intron 545 
R29 GGTAAATTCCTGAACTCTGCTG 
  
F30 AGCAGAGTTCAGGAATTTACCA Intron 526 
R30 GAAATGACGGGGTCTCACTT 
  
F31 AAGTGAGACCCCGTCATTTC Intron 522 
R31 AATGGGAGTTGGCAGCTAAG 
  
F32 AATTCATCCTTCCAGTTGAGC Intron 599 
R32 GTGAGCCGTGATTGTACCAC 
  
F33 GTGGTACAATCACGGCTCAC Intron 533 
R33 TCTGCTGTGTGTCAAATTTCC 
  
F34 GGAAATTTGACACACAGCAGA Intron 547 
R34 AGTGAAGGTCATGGATGCTG 
  
F35 CAGCATCCATGACCTTCACT Intron 357 
R35 ACCTGTAATCCCAGCTACCC 
  
F36 GATTACAGGTGCCCACCAC Intron 618 
R36 AAAAACAGCCCTGAAAGTGC 
  
F37 GGCTGTTTTTCTCTCCTTGC Intron 611 
R37 CAGAAATGTCTCCAGCTCTCC 
  
F38 CCTGGAGAGCTGGAGACATT Intron 570 
R38 GGAGGAAACAGTGGGGATAA 
  
F39 GTTTCCTCCACTCACCCTGT Intron 612 
R39 CCTTGGGCTTGTGTTTTCTT 
  
F40 ACTCCAGCTTGGGTGACAG Intron 454 
R40 AGCCTTAGGTGCTTACTCTGCT 
  
F41 GGATGTAGCAAGATCCTTATGAAA Intron 482 
R41 TGTGAGTGATGGGTGAGACA 
  
F42 TGTCTCACCCATCACTCACA Intron 479 
R42 TCACTAGCAACAAGCAGATGG 
  
F43 TGCATACCATCTGCTTGTTG Intron 450 
R43 CCACACCAAGAGGAACTGAA 
  
F44 ACTGTCATCCTTGTGAGAGTCTG Intron 478 
R44 CCTGGAGACCCCTTCATACA 
  
   F45 GGGTTAGGCCCTTCTCATGT Exon 2 522 
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R45 CGCTGTCAAAGGGATCAGA 
  
F46 CCAGCTTTTATAGGGCTTGC Exon 2 568 
R46 CATCATCACCCAGTCGACAG 
  
F47 CTGTCGACTGGGTGATGATG Exon 2 546 
R47 GAACAGCATCCAAATCACCA 
  
F48 TTGAACAGCAGTGTCCCATC Exon 2 663 
R48 GGCCATATGACTTGCTTTCC 
  
F49 GTGGGAAAGGGTCCAGATTT Exon 2 502 
R49 GGTTCATTGCACTTGCACAC 
  
F=Forward primer, R=Reverse primer 
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Products were sequenced with forward or reverse primer and BigDye
®
 Terminators by ABI 
PRISM 3730 Genetic Analyzer (Applied Biosystems). SNPs were detected by Sequencher 
software v4.8 (Gene Codes, Ann Arbor, MI, USA). 
 
Cell lines 
Three breast cancer cell lines,MCF7, T-47D, and BT-474, were obtained from the American 
Type Culture Collection (ATCC, Manassas, VA). T-47D and BT-474 cells were grown in 
RPMI 1640 medium, and MCF7 cells were in Eagle's minimal essential medium (EMEM) 
supplemented with 10% fetal bovine serum (FBS, Life Technologies, Carlsbad, CA) and 1% 
antibiotic/antimycotic solution (Sigma, St. Louis, MO). were maintained at 37
o
C in an 
atmosphere of humidified air with 5% CO2. 
 
Preparation of reporter plasmids 
The genomic regions encompassing the three SNPs, SNP X, SNP Y and SNP Z, were 
amplified by PCR using different sets of primers (Table 5) with genomic DNA from the 
subjects as templates. The reaction was performed in a reaction mixture of 50μl containing 
KOD buffer, 5mM of dNTP, 50 pmol of each primer, 30 ng of genomic DNA, and KOD Taq 
polymerase (TOYOBO, Tokyo, Japan). All of the reaction involved initial denaturation at 
94°C for 2 min, followed by 35 cycles at 94°C for 15 s, 58°C for 30s, and 72°C for 2-5 min 
on a GeneAmp PCR System 9700 (Applied Biosystems, USA). PCR products were purified 
with QIAquick PCR Purification Kit (Quiagen, Valencia, CA), digested with appropriate 
restriction enzymes, and cloned into the appropriate enzyme sites of pGL3-Promoter vector 
or pGL3-basic vector (Promega, Madison, WI).The reporter plasmids, pGL3A_Major and 
pGL3A_Minor, included a genomic region A (between -2,151 and -571) in the 5’-flanking 
region of SIAH2encompassing SNP X upstream of the luciferase gene. The reporter 
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Table 5. Primer sequencesfor reporter plasmids. 
 
Plasmid’ 
name 
 
Forward primer Reverse primer 
Restriction 
enzyme_1 
Restriction 
enzyme_2 
Length of 
product 
(bp) 
pGL3A 5’CTCGGTATCCTATCCAAAACTCAGGTTCAGC 3’ 5’TCGAGATCTCGTCGAAGTCCTCTGG 3’ Kpn l Bglll 1,580 
pGL3PB 5’TGGTACCAGCAGGTCCTCTTA 3’ 5’CTTGGGAAGACTTTGGCATAA3’ Nhe l Bglll 1.089 
pGL3PC 5’TGCCCCAGTAATGAATGTCCT 3’ 5’TGTGGTCATTTGTGGCTTCA 3’ Mlu l Xho l 1.905 
pGL3PB290 5’AAGGGAGGGTGTGTTTAGCC 3’ 5’ACCTGGCATGGAAGAGTGAG 3’ Mlu l Xho l 290 
pGL3PB60 5’TCATGGAGAACCAGTTTTGTG 3’ 5’TTGCTTGAACATGCACTTTG 3’ Mlu l Xho l 60 
pGL3A: construct of region A using pGL3-Basic. 
pGL3PB: construct of region B using pGL3-promoter. 
pGL3PC: construct of region C using pGL3-promoter. 
 pGL3PB290: construct of region B 290bp using pGL3-promoter. 
pGL3PB60: construct of region B 60pb using pGL3-promoter. 
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plasmids, pGL3PB_Major and pGL3PB_Minor, included a genomic region B (between 
+10,063 and +11,152) in the intron 1 of SIAH2 encompassing SNP Y and plasmids, 
pGL3PC_Major and pGL3PC_Minor, included a genomic region C (between +13,956 and 
15,864) in the intron 1 encompassing SNP Z upstream of SV40 promoter. Plasmids DNA was 
purified from bacterial cells using NucleoBond® Xtra plasmid purification kit according to 
the supplier’s protocol. 
 
Site directed mutagenesis  
Site direct mutagenesis was performed with Quick Change II XL Site-Directed Mutagenesis 
Kit (Agilent Technologies, Santa Clara, CA) according to the manufacture’s instruction. 
Primer sequences used for the mutagenesis were shown in Table 6. I changed A to G in the 
SNP Y1 (A/G) using forward primer 5`-
CACCTGCACAACCACGTAACTGCCCTGACAG-3` and reverse primer 5`-
CTGTCAGGGCAGTTACGTGGTTGTGCAGGTG-3` and G into T in the SNP using 
forward primer 5`-CACCTGCACAACCACTTAACTGCCCTGACAG-3` and reverse primer  
5`- CTGTCAGGGCAGTTAAGTGGTTGTGCAGGTG -3`.  
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Table 6. Primer sequences for site directed mutagenesis 
B209_major_mutant_F CACCTGCACAACCACGTAACTGCCCTGACAG 
B209_major_mutant_R CTGTCAGGGCAGTTACGTGGTTGTGCAGGTG 
                  B209_minor_mutant_F CACCTGCACAACCACTTAACTGCCCTGACAG 
 B209_minor_mutant_R CTGTCAGGGCAGTTAAGTGGTTGTGCAGGTG 
B209_major_mutant_F:  Forward primer for region B 290 bp has mutant major allele of  Y1 
B209_major_mutant_R: Reverse primer for region B 290 bp has mutant major allele of   Y1 
B209_minor_mutant_F: Forward primer for region B 290 bp has mutant minor allele of  Y1 
B209_minor_mutant_R: Reverse primer for region B 290 bp has mutant minor allele of  Y1 
Under line indicates mutated nucleotide of Y1 in the primers. 
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Dual-Luciferase reporter assay 
BT-474 (2× 10
5
cells /well) or T-47D (1.5× 10
5
cells /well) cells seeded on six-well plates 
were transfected with 1g of reporter plasmids and 0.1 g of pRL-TK plasmids (Promega) by 
FuGENE
®
6 reagent (Roche, Indianapolis, USA). The cells were harvested after 24 h of 
incubation, and luciferase activities were measured using dual luciferase assay system 
(TOYO B-Net, Tokyo, Japan). 
 
17 β estradiol treatment  
MCF7 (2× 10
5
cells /well) and T-47D (1.5× 10
5
cells /well) cells were grownin phenol red 
free-medium supplemented with 5% FBS treated with dextran coated charcoal to remove the 
steroid hormone agonist and 1% streptomycin for 24 hrs before the transfection. The cells 
were co-transected with reporter plasmids and pRL-TK Renilla luciferase plasmid using 
FuGENE
® 
6 Transfection Reagent according to the supplier’s protocol. Twenty-four hrs after 
transfection, the cells were treated with 17β-estradiol (Sigma) freshly resolved in ethanol at 
the concentration of 10 nM, or vehicle (ethanol). Reporter activities were measured after 24 
hrs of the treatment. 
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Chapter 4 Results 
Identification of SNPs associated with HRP breast cancer 
To identify genetic variants susceptible to HRP breast cancer in Japanese population, I 
performed an initial case-control study using 1086 female patients and 1816 female controls 
by GWAS with Illumina HumanHap 610k Bead Chip. A SNP quality control standard was 
applied for the study, and SNPs showing p-value of Hardy-Weinberg equilibrium more than 
1.0 x 10
-6
 in controls and SNPs with call rate lower than 0.99 in both cases and controls were 
excluded. After this quality check of SNP genotyping data, a total of 453,627 SNPs were 
selected for further analysis. Principal component analysis revealed that all the subjects 
participating in this study were clustered in the HapMap Asian population (Figure 1). The 
quantile-quantile plot (Q-Q plot), a plot of the percentiles (or quintiles) of a standard normal 
distribution against the corresponding percentiles of the observed data, showed a highly 
positive association between the expected and observed p-values. The observations follow 
approximately a normal distribution because the resulting plot is roughly a straight line with a 
positive slope as shown in Figure 2. The genomic inflation factor (lGC) of the test statistic in 
this study was 1.053 indicating a very low possibility of false-positive associations resulted 
from the population stratification.  
Although no SNP achieved genome-wide significance level P-value <5×10
-8
, 46 SNPs in 
various chromosomes showed suggestive association (P-value <1×10
-4
) as illustrated in 
Manhattan plot in Figure 3. Among these 46 SNPs, I excluded 13 SNPs possessing strong LD 
(r
2
>0.8) with the others, and selected 33 SNPs for replication study. I included four additional 
SNPs (rs1292011, rs3803662, rs2981579 and rs3750817) that were previously reported their 
association with breast cancer and showed P-value of <1.0×10
-2
 in our GWAS. A total of 37 
SNPs (Table 7) were analyzed using an independent set of 1653 female patients and 2797 
female controls. In this replication study, a SNP, rs6788895, was successfully replicated with 
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Figure1. Principal component analysis (PCA) plot of samples enrolled in the genome wide 
association study (GWAS) of hormonal receptor positive breast cancer. All cases and 
controls who participated in the GWAS were plotted based on eigenvectors1 and 2 obtained 
from the PCA, along with the European(CEU), African(YRI), and Japanese(JPT) and 
Chinese(CHB) individuals obtained from the PhaseII HapMap database. 
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Figure2.A quantile-quantile (Q.Q) plot for GWAS of hormonal receptor positive breast 
cancer. Horizontal and vertical lines represent expected P values under a null distribution and 
observed P values, respectively. Fall the SNPs were not associated with the disease, all plots 
would lie on the line y=x. 
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Figure 3. Manhattan plot for GWAS of HRP breast cancer indicating _log10P of the Cochran–Armitage trend test for 453627 single-nucleotide 
polymorphisms (SNPs) plotted against their respective positions on each chromosome. 
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Table 7. Associations of the 33 SNPs identifiedin GWAS with HRP breast cancer. 
  
case control 
      
SNP Stage 11 12 22 MAF 11 12 22 MAF Passoc
a
 OR 
 
Phet
b
 chr Gene 
rs708766 GWAS 691 345 50 0.2 1273 498 45 0.16 3.65E-05 1.33 (1.16-1.53) 8.99E-03 1 ITPKB 
 
Rep 1114 463 74 0.19 1909 785 103 0.18 3.61E-01 1.05 (0.94-1.18) 
   
 
Combined 1805 808 124 0.19 3182 1283 148 0.17 1.07E-03 1.16 (1.06-1.26) 
   
rs53915 GWAS 567 434 85 0.28 1081 650 85 0.23 6.74E-06 1.32 (1.17-1.49) 1.26E-05 2 CTNNA2 
 
Rep 967 589 94 0.24 1586 1029 182 0.25 1.53E-01 1.08 (0.97-1.19) 
   
 
Combined 1534 1023 179 0.25 2667 1679 267 0.24 8.88E-02 1.07 (0.99-1.16) 
   
rs1012357 GWAS 648 388 50 0.22 966 710 140 0.27 5.19E-05 1.29 (1.14-1.46) 4.14E-05 2 KIAA1715 
 
Rep 890 640 122 0.27 1566 1045 186 0.25 1.40E-01 1.08 (0.98-1.19) 
   
 
Combined 1538 1028 172 0.25 2532 1755 326 0.26 1.67E-01 1.06 (0.98-1.14) 
   
rs560737 GWAS 11 216 859 0.11 10 265 1541 0.08 5.65E-05 1.45 (1.21-1.73) 4.00E-02 2 SOX11 
 
Rep 43 262 1346 0.11 28 470 2299 0.09 9.29E-02 1.14 (0.98-1.31) 
   
 
Combined 54 478 2205 0.11 38 735 3840 0.09 1.76E-04 1.24 (1.11-1.39) 
   
rs6788895 GWAS 106 456 524 0.31 242 832 742 0.36 2.34E-05 1.28 (1.14-1.43) 2.33E-01 3 SIAH2 
 
Rep 164 694 786 0.31 337 1265 1195 0.35 5.77E-04 1.18 (1.07-1.29) 
   
 
Combined 270 1150 1310 0.31 579 2097 1937 0.35 9.43E-08 1.22 (1.13-1.31) 
   
rs9835984 GWAS 80 459 547 0.28 214 791 811 0.34 6.24E-05 1.27 (1.13-1.42) 6.83E-05 3 NUP210 
 
Rep 185 721 746 0.33 295 1179 1322 0.32 1.81E-01 1.07 (0.97-1.17) 
   
 
Combined 233 1148 1259 0.31 509 1970 2133 0.32 2.36E-02 1.09 (1.01-1.17) 
   
rs10017875 GWAS 87 431 568 0.28 101 640 1074 0.23 8.08E-05 1.28 (1.13-1.44) 1.01E-03 4 LOC727819 
 
Rep 116 580 956 0.25 168 1057 1571 0.25 7.26E-01 1.02 (0.92-1.12) 
   
 
Combined 203 1011 1524 0.26 269 1697 2645 0.24 2.70E-02 1.09 (1.01-1.18) 
   
rs6844819 GWAS 322 522 242 0.46 632 882 302 0.41 6.37E-05 1.25 (1.12-1.39) 1.80E-02 4 LOC645174 
 
Rep 514 782 356 0.45 892 1348 551 0.44 2.30E-01 1.06 (0.97-1.15) 
   
 
Combined 836 1304 598 0.46 1524 2230 853 0.43 6.05E-04 1.13 (1.05-1.2) 
   
rs4921443 GWAS 10 157 919 0.08 3 187 1626 0.05 2.01E-05 1.58 (1.28-1.95) 2.78E-03 5 GABRG2 
 
Rep 7 201 1444 0.07 11 329 2457 0.06 6.64E-01 1.04 (0.87-1.24) 
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Combined 17 358 2363 0.07 14 516 4083 0.06 2.48E-03 1.23 (1.08-1.41) 
   
rs10039851 GWAS 625 396 65 0.24 1181 562 71 0.19 1.60E-05 1.33 (1.17-1.51) 1.38E-02 5 GFPT2 
 
Rep 1002 534 116 0.23 1713 946 138 0.22 1.51E-01 1.08 (0.97-1.2) 
   
 
Combined 1627 930 181 0.24 2894 1508 209 0.21 1.55E-04 1.17 (1.08-1.27) 
   
rs2278386 GWAS 146 525 415 0.38 344 875 597 0.43 4.99E-05 1.25 (1.12-1.4) 6.44E-04 5 SLIT3 
 
Rep 283 818 550 0.42 484 1353 960 0.41 6.95E-01 1.02 (0.93-1.11) 
   
 
Combined 429 1343 965 0.4 828 2228 1557 0.42 2.44E-02 1.08 (1.01-1.16) 
   
rs9456909 GWAS 16 260 809 0.13 65 516 1234 0.18 1.59E-05 1.39 (1.2-1.62) 6.50E-04 6 LOC728275 
 
Rep 54 461 1137 0.17 93 780 1923 0.17 9.49E-01 1.00 (0.9-1.12) 
   
 
Combined 70 721 1946 0.18 158 1296 3157 0.17 6.59E-03 1.13 (1.04-1.24) 
   
rs13199020 GWAS 9 172 905 0.09 24 401 1391 0.12 1.92E-05 1.47 (1.23-1.76) 6.16E-03 6 FAM8A6P 
 
Rep 18 322 1312 0.11 38 570 2189 0.12 3.04E-01 1.07 (0.94-1.23) 
   
 
Combined 27 494 2217 0.1 62 971 3580 0.12 5.21E-04 1.21 (1.09-1.35) 
   
rs6453815 GWAS 93 459 534 0.3 208 845 763 0.35 6.87E-05 1.26 (1.12-1.41) 8.09E-04 6 COL12A1 
 
Rep 190 691 770 0.32 289 1211 1297 0.32 6.61E-01 1.02 (0.93-1.12) 
   
 
Combined 283 1150 1304 0.31 497 2056 2060 0.33 3.26E-02 1.08 (1.01-1.16) 
   
rs10456973 GWAS 697 357 32 0.19 1290 490 36 0.15 8.98E-05 1.31 (1.14-1.51) 9.34E-05 6 PTPRK 
 
Rep 1170 433 48 0.16 1915 799 83 0.17 1.36E-01 1.09 (0.97-1.23) 
   
 
Combined 1867 790 80 0.17 3205 1289 119 0.17 2.06E-01 1.06 (0.97-1.16) 
   
rs10250216 GWAS 16 301 769 0.15 21 377 1418 0.16 2.21E-05 1.39 (1.19-1.62) 6.09E-03 7 BBS9 
 
Rep 37 377 1238 0.14 51 630 2116 0.13 4.53E-01 1.05 (0.93-1.19) 
   
 
Combined 53 678 2007 0.14 72 1007 3534 0.12 1.39E-03 1.17 (1.06-1.29) 
   
rs7814396 GWAS 680 362 44 0.21 1022 669 125 0.25 7.72E-05 1.30 (1.14-1.47) 6.56E-04 8 SOX17 
 
Rep 945 600 106 0.25 1605 1032 160 0.24 6.54E-01 1.02 (0.93-1.13) 
   
 
Combined 1625 962 150 0.23 2627 1701 285 0.25 3.29E-02 1.09 (1.01-1.18) 
   
rs822304 GWAS 477 490 119 0.34 685 851 280 0.39 4.91E-05 1.26 (1.13-1.41) 2.37E-03 8 MRPL49P2 
 
Rep 652 767 232 0.37 1088 1319 390 0.38 8.20E-01 1.01 (0.92-1.1) 
   
 
Combined 1129 1257 351 0.36 1773 2170 670 0.38 6.25E-03 1.10 (1.03-1.18) 
   
rs4741635 GWAS 174 509 401 0.40 199 847 768 0.34 5.84E-05 1.25 (1.12-1.4) 1.30E-02 9 C9orf66 
 
Rep 238 750 663 0.37 365 1287 1142 0.36 3.31E-01 1.05 (0.96-1.14) 
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Combined 412 1259 1064 0.38 564 2134 1910 0.35 1.09E-03 1.12 (1.05-1.2) 
   
rs6602097 GWAS 414 543 129 0.37 842 788 186 0.32 9.63E-05 1.25 (1.11-1.39) 1.84E-02 10 PTER 
 
Rep 684 796 171 0.34 1247 1230 320 0.33 3.14E-01 1.05 (0.96-1.15) 
   
 
Combined 1098 1339 300 0.35 2089 2018 506 0.33 1.24E-03 1.12 (1.05-1.2) 
   
rs1028722 GWAS 51 366 669 0.22 58 514 1244 0.17 8.42E-05 1.31 (1.15-1.5) 1.78E-04 14 
CHORDC2
P 
 
Rep 62 470 1120 0.18 107 845 1845 0.19 2.70E-01 1.07 (0.95-1.19) 
   
 
Combined 113 836 1789 0.19 165 1359 3089 0.18 1.06E-01 1.07 (0.99-1.17) 
   
rs12591707 GWAS 35 332 719 0.19 80 684 1052 0.23 1.49E-05 1.33 (1.17-1.52) 3.16E-04 15 
LOC100128
104 
 
Rep 80 559 1011 0.22 121 930 1689 0.21 6.57E-01 1.02 (0.92-1.14) 
   
 
Combined 115 891 1730 0.2 201 1614 2741 0.22 1.87E-02 1.10 (1.02-1.2) 
   
rs11076442 GWAS 114 472 493 0.32 266 832 715 0.38 8.08E-05 1.26 (1.12-1.41) 4.80E-03 16 LOC643358 
 
Rep 215 782 654 0.37 395 1280 1107 0.37 6.39E-01 1.02 (0.93-1.12) 
   
 
Combined 329 1254 1147 0.35 661 2112 1822 0.37 4.47E-03 1.11 (1.03-1.19) 
   
rs4793427 GWAS 961 123 2 0.06 1517 279 20 0.09 5.90E-05 1.55 (1.25-1.92) 5.82E-03 17 LOC727973 
 
Rep 1427 214 11 0.07 2395 380 21 0.08 4.88E-01 1.06 (0.9-1.25) 
   
 
Combined 2388 337 13 0.07 3912 659 41 0.08 2.03E-03 1.23 (1.08-1.4) 
   
rs7219201 GWAS 830 240 16 0.13 1496 308 12 0.09 3.96E-05 1.42 (1.2-1.69) 9.94E-03 17 BCAS3 
 
Rep 1305 315 32 0.11 2229 531 37 0.11 3.49E-01 1.07 (0.93-1.22) 
   
 
Combined 2135 555 48 0.12 3725 839 49 0.10 1.17E-03 1.19 (1.07-1.33) 
   
rs871739 GWAS 36 340 710 0.19 104 640 1072 0.23 9.48E-05 1.30 (1.14-1.48) 1.07E-02 17 
LOC100133
332 
 
Rep 78 541 1033 0.21 126 969 1701 0.22 4.12E-01 1.04 (0.94-1.16) 
   
 
Combined 114 881 1743 0.2 230 1609 2773 0.22 1.92E-03 1.14 (1.05-1.24) 
   
rs6040836 GWAS 500 472 114 0.32 714 845 257 0.37 6.86E-05 1.26 (1.12-1.41) 1.93E-05 20 LOC728573 
 
Rep 604 746 202 0.37 1188 1257 352 0.35 6.28E-02 1.09 (1-1.19) 
   
 
Combined 1104 1218 316 0.35 1902 2102 609 0.36 2.66E-01 1.04 (0.97-1.12) 
   
rs6036227 GWAS 43 328 715 0.19 43 461 1312 0.15 8.28E-05 1.33 (1.15-1.53) 2.20E-02 20 CYB5P4 
 
Rep 42 424 1186 0.15 58 696 2043 0.15 2.71E-01 1.07 (0.95-1.21) 
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Combined 85 752 1901 0.17 101 1157 3355 0.15 6.85E-04 1.17 (1.07-1.28) 
   
rs2853218 GWAS 24 291 771 0.16 30 359 1427 0.12 9.67E-06 1.42 (1.22-1.65) 5.95E-04 20 ATRN 
 
Rep 37 356 1259 0.13 43 643 2111 0.13 9.81E-01 1.00 (0.88-1.14) 
   
 
Combined 61 647 2030 0.14 73 1002 3538 0.12 5.60E-03 1.15 (1.04-1.27) 
   
rs8129581 GWAS 99 474 513 0.26 128 685 1003 0.26 3.63E-05 1.28 (1.14-1.44) 3.90E-03 21 PPIAL3 
 
Rep 142 640 870 0.27 220 1096 1479 0.27 6.23E-01 1.02 (0.93-1.13) 
   
 
Combined 241 1114 1383 0.27 348 1781 2482 0.27 2.99E-03 1.12 (1.04-1.21) 
   
rs17820958 GWAS 171 549 366 0.41 383 932 501 0.47 1.56E-05 1.26 (1.13-1.41) 4.13E-03 22 PATZ1 
 
Rep 328 807 517 0.44 584 1350 861 0.45 4.87E-01 1.03 (0.95-1.12) 
   
 
Combined 499 1356 883 0.43 967 2282 1362 0.46 1.28E-03 1.12 (1.04-1.19) 
   
rs5997921 GWAS 194 550 342 0.43 415 934 467 0.49 5.48E-05 1.24 (1.12-1.38) 5.83E-03 22 LIMK2 
 
Rep 350 830 471 0.46 630 1365 802 0.47 5.92E-01 1.02 (0.94-1.12) 
   
 
Combined 544 1380 813 0.45 1045 2299 1269 0.48 3.40E-03 1.11 (1.03-1.18) 
   
rs1034587 GWAS 186 556 344 0.37 246 858 711 0.37 2.39E-05 1.26 (1.13-1.4) 5.79E-04 22 PIK3IP1 
 
Rep 243 792 617 0.39 447 1289 1061 0.39 7.50E-01 1.01 (0.93-1.11) 
   
 
Combined 429 1348 961 0.38 693 2147 1772 0.38 1.73E-02 1.09 (1.01-1.16) 
   
MAF, Minor allele frequency; OR, Odds ratio (Calculated based on non susceptible allele); CI, Confidence intervals 
a
P-assoc: P-value for GWAS and replication study obtained from the Cochran-Armitage trend test; P-value for the combined study obtained from simple 
combined analysis test 
b 
P-het: P-value for heterogeneity test obtained from the Breslow-Day test 
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the P-value of <1.35×10
-3
 even after the Bonferroni correction (0.05/37) as shown in Table 8. 
Combined analysis of the results of the GWAS and the replication study suggested strong 
association of the locus of the SIAH2 gene on chromosome 3q25.1 (rs6788895, Pcombined of 
9.43×10
-8
 with OR of 1.22, 95% confidence interval 1.13–1.31) without any significant 
heterogeneity between the two studies (Pheterogeneity= 2.33×10
-01
). I further performed subgroup 
analysis to examine the  association of rs6788895  with the subgroups of breast cancer; an 
invasive papilloductal breast cancer group and a HER2-negative breast cancer group, and 
found significant associations with them (Pcombined=3.61×10
-07
, 6.78×10
-06
, OR=1.23, 1.21 
respectively) although they did not reach to the genome-wide significant level (Table 9). 
Imputation analysis of this locus identified nine additional SNPs in strong LD (r
2
 > 0.8) with 
rs6788895, and they showed similar levels of association with HRP tumors (Figure 4). I 
performed re-sequencing of 22,353 bps corresponding to the SIAH2 gene and identified 10 
novel genetic variations in addition to 37 variations reported previously. After the exclusion 
of 25 SNPs showing strong LD with rs6788895, I further genotyped 22 of the 47 variants. As 
a result, no genetic variant showed significant association with HRP breast cancer (Table 10 
and Table 11). Using our sample sets, I additionally investigated the 22 SNPs (Table 12) that 
were reported to be associatedwith HRP breast cancer
25, 34-41
. Moderate association of four 
genetic variants, rs1292011, rs3803662, rs2981579 and rs3750817, was observed in our 
GWAS sample set (PGWAS= 5.89×10
-02
, 6.95×10
-03
, 8.68×10
-04
 and 5.03×10
-04
, respectively). 
Further analysis using the replication set found significant association in two of the four 
SNPs, rs3750817 (Preplication=5.39×10
-5
, OR =1.22) and rs2981579 (Preplication=1.21×10
-3
, 
OR=1.20). Both SNPs are located within intron 2 of the fibroblast growth factor receptor 2 
(FGFR2) gene. The combined analysis of the GWAS and replication phases of rs3750817 
revealed strong association with Pcombined=8.47×10
-08
 (OR=1.22) and that of rs2981579 was   
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Table 8. Association of SNP rs6788895 with HRP breast cancer 
 
              Case Control    
Passoc
1
 
   
OR 
   
(95% CI) 
   
Phet
2
 Chr. Chrloc. SNP RA Stage TT TG GG RAF TT TG GG RAF 
3 151950498 rs6788895 G GWAS 106 456 524 0.69 242 832 742 0.64 2.34E-05 1.28 (1.14-1.43) 
 
    
Rep 164 694 786 0.69 337 1,265 1,195 0.65 5.77E-04 1.18 (1.07-1.29) 2.33E-01 
    
Combined 270 1,150 1,310 0.69 579 2,097 1,937 0.65 9.43E-08 1.22 (1.13-1.31) 
 
Chr., chromosome; chrloc., chromosomal location (bp); RA, risk allele; 11, homozygous non risk genotype; 12, heterozygous genotype; 
22, homozygous risk genotype; RAF, risk allele frequency; OR, odds ratio (calculated based on the risk allele); CI, confidence 
intervals; Rep, replication.  
1
Passoc, P value for the GWAS and replication study obtained from the Cochran-Armitage trend test and P value for the combined 
study obtained from the simple combined test.  
2
Phet, P value for heterogeneity test obtained from the Breslow-Day test. 
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Table 9. Associations of rs6788895 in the subgroups 
  
Case Control 
    
 
 Stage TT TG GG RAF TT TG GG RAF 
risk 
allele 
Passoc
a OR (95% CI) Phetb 
Invasive 
papilloductal 
1st 56 316 346 0.70 242 832 742 0.64 G 1.37E-05 1.34 (1.17-1.53) 1.00E-01 
Rep 134 578 640 0.69 337 1265 1195 0.65 G 2.32E-03 1.17 (1.06-1.29)  
Total 190 894 986 0.69 579 2097 1937 0.65 G 3.61E-07 1.23 (1.13-1.33)  
Her-2 receptor 
negative 
1st 75 314 346 0.68 242 832 742 0.64 G 1.63E-03 1.23 (1.08-1.4) 7.33E-01 
Rep 129 411 549 0.69 337 1265 1195 0.65 G 1.13E-03 1.20 (1.08-1.33)  
Total 204 725 895 0.69 579 2097 1937 0.65 G 6.78E-06 1.21 (1.11-1.31)  
Hormonal 
receptor negative   
1st  44  176  178  0.33 242  832  742  0.36  G 1.03E-01   1.15  (1.07-1.13)  
 Her-2 receptor 
positive  
1st  23  72  89  0.32 242  832  742  0.36  G 1.15E-01   1.2  (1. 07-1.23)   
11, homozygous non risk genotype; 12, heterozygous genotype; 22, homozygous risk genotype; RAF, risk allele frequency; OR, odds ratio 
(calculated based on the risk allele); CI, confidence intervals; Rep, replication.  
a
Passoc, P value for the GWAS and replication study obtained from the Cochran-Armitage trend test and P value for the combined study obtained 
from the simple combined test.  
b
Phet, P value for heterogeneity test obtained from the Breslow-Day test. 
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Figure4. Regional association plots of the locus associated with HRP breast cancer on chromosomes 3q25.1 (intron of seven in absentia 
homolog 2 (SIAH2) For each plot, _log10P of the Cochran–Armitage trend test of SNPs in GWAS was plotted against relative chromosomal 
locations. The square and rounded signs represent imputed and genotyped SNPs, respectively. All SNPs are color coded as red (r
2
=0.8–1.0), 
orange (r
2
=0.6–0.8), green (r2=0.4–0.6), light blue (r2=0.4–0.6), and dark blue (r2=0.2) according to their pair wise r2 to the marker SNP. The 
marker SNP is represented in purple color. SNP positions followed NCBI build 36 coordinates. Estimated recombination rates (cM/Mb) are 
plotted as a blue line. 
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Table 10. Association study of reported SNPs resulted from re-sequence analysis in HRP breast cancer 
SNP 
Case Control MAF 
Passoc
a
 OR 95% CI 
11 12 22 11 12 22 case Ctrl 
rs6788895 221 947 1098 100 332 296 0.31 0.37 3.36E-05 1.30 (1.15-1.47) 
rs476663 959 988 316 305 336 87 0.36 0.35 6.02E-01 1.03 (0.91-1.17) 
rs7615292 1014 1060 192 315 336 77 0.32 0.34 1.88E-01 1.08 (0.96-1.23) 
rs7636866 321 974 970 93 316 319 0.36 0.34 4.20E-01 1.05 (0.93-1.19) 
rs2116684 333 1033 900 126 312 288 0.37 0.39 3.65E-01 1.06 (0.94-1.2) 
rs19862837 253 1020 993 62 349 316 0.34 0.33 4.16E-01 1.05 (0.93-1.19) 
rs57359526 274 1009 983 112 296 318 0.34 0.36 3.19E-01 1.07 (0.94-1.21) 
rs6789306 287 991 988 102 313 313 0.35 0.36 5.05E-01 1.04 (0.92-1.18) 
rs1148369 38 109 2118 0 68 660 0.04 0.05 3.90E-01 1.15 (0.87-1.53) 
rs76182650 909 1100 257 307 335 86 0.36 0.35 5.73E-01 1.04 (0.91-1.17) 
rs1733711 261 974 1031 90 301 335 0.33 0.33 9.35E-01 1.01 (0.89-1.14) 
rs61628582 930 1036 300 301 345 80 0.36 0.35 3.60E-01 1.06 (0.94-1.2) 
MAF, minor allele frequency, OR, odds ratio; CI, confidence intervals. 
a
Passoc, P value obtained from the Cochran-Armitage trend test. 
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Table 11. Association study of unreported SNPs resulted from re-sequence analysis in HRP breast cancer 
SNP  position 
Case Control MAF 
Passoc
a
 OR 95% CI 
11 12 22 11 12 22 case Ctrl 
150481266 5' UTR 10 179 2074 3 68 657 0.04 0.05 2.88E-01 1.16 (0.89-1.53) 
150471735 Intron 201 1036 1029 76 332 320 0.32 0.33 2.71E-01 1.07 (0.94-1.21) 
150470898 Intron 2128 105 33 685 33 10 0.04 0.04 8.42E-01 1.04 (0.76-1.42) 
150467858 Intron 2226 37 3 718 8 2 0.01 0.01 6.89E-01 1.15 (0.61-2.19) 
150466004 Intron 2138 106 22 686 40 2 0.03 0.03 6.25E-01 1.10 (0.78-1.55) 
150465616 Intron 2148 112 6 700 26 2 0.03 0.02 1.73E-01 1.34 (0.89-2) 
150465581 Intron 2123 110 33 690 28 10 0.04 0.03 3.79E-01 1.19 (0.86-1.64) 
150461443 Intron 2186 76 4 710 17 1 0.02 0.01 1.78E-01 1.43 (0.87-2.36) 
150460001 exon 2 2138 120 8 686 41 1 0.03 0.03 9.29E-01 1.02 (0.72-1.44) 
150459679 3` UTR 0 100 2166 0 36 692 0.022 0.02 5.49E-01 1.12 (0.76-1.65) 
MAF, minor allele frequency, OR, odds ratio; CI, confidence intervals. 
a
Passoc, P value obtained from the Cochran-Armitage trend test. 
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Table 12: GWAS of HRP breast cancer reported in other population 
 
Case Control 
   
 
SNP 11 12 22 11 12 22 Passoc
a
 OR (95% CI) Ref 
rs3750817 (FGFR2) 256 545 285 519 901 396 5.03E-04 1.21 (1.09-1.34) 
34
 
rs2981579 (FGFR2) 253 538 295 346 889 580 8.68E-04 0.83 (0.75-0.93) 
42
 
rs1219648 (FGFR2) 393 524 169 741 844 231 4.34E-03 1.17 (1.05-1.31) 
43
 
         rs1292011 (12q24) 582 422 82 914 738 163 5.89E-02 0.89 (0.79-1) 
44
 
rs11249433 (1p11.2) 1013 71 2 1717 98 1 1.32E-01 1.26 (0.93-1.71) 
45
 
rs7752591 (C6orf97) 171 530 384 276 835 705 1.33E-01 0.92 (0.82-1.03) 
46
 
      rs12500093  (MTNR1A) 76 411 599 133 722 961 2.86E-01 1.07 (0.95-1.2) 
38
 
rs2380205 (TRNAV) 5 155 926 9 231 1576 2.88E-01 0.90 (0.73-1.1) 
38
 
 rs7703618 (MRPS30) 127 488 471 226 838 752 2.94E-01 1.06 (0.95-1.19) 
47
 
         rs1011970 (ANRIL) 3 119 964 11 212 1593 2.97E-01 1.13 (0.9-1.41) 
38
 
rs13387042 (TNP1) 11 223 852 23 395 1398 3.20E-01 1.09 (0.92-1.28) 
48
 
rs6929137(C6orf97) 76 429 580 128 680 1008 4.02E-01 0.95 (0.84-1.07) 
46
 
rs490361(NCOA7) 693 349 44 1186 561 69 4.18E-01 1.06 (0.92-1.21) 
36
 
rs3734805 (C6orf97) 598 422 66 1038 664 114 4.20E-01 1.05 (0.93-1.19) 
46
 
rs9383932 (C6orf97) 454 498 133 786 818 212 4.33E-01 1.05 (0.94-1.17) 
46
 
rs4866929 (HCN1) 392 508 186 651 890 275 5.13E-01 1.04 (0.93-1.16) 
47
 
rs9375411(NCOA7) 212 544 330 357 884 575 6.73E-01 0.98 (0.88-1.09) 
36
 
rs10454853 (5p13.3) 789 268 29 1305 463 48 6.99E-01 0.97 (0.84-1.13) 
49
 
rs852003 (C6orf97) 124 486 476 217 778 821 7.44E-01 0.98 (0.88-1.1) 
46
 
rs2823093( NRIP1) 0 27 1059 1 46 1769 7.99E-01 1.06 (0.66-1.71) 
44
 
rs4973768 (SLC4A7) 38 334 714 64 564 1188 8.68E-01 1.01 (0.88-1.16) 
48
 
rs549438 (NCOA7) 615 408 63 1028 677 111 8.86E-01 0.99 (0.88-1.12) 
36
 
OR, odds ratio; CI, confidence intervals. 
a
Passoc, P value for the GWAS obtained from the Cochran-Armitage trend test. 
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1.77×10
-06
 (OR=1.20) (Table 13). Imputation analysis of this locus identified three additional 
SNPs (rs9420318, rs11199914 and rs10736303) that showed similar levels of association 
with rs3750817 (Figure 5). 
To identify functional variants of the SIAH2 gene, I focused on the 25 SNPs showing strong 
LD with rs6788895 that had a significant association with HRP-breast cancer. The SIAH2 
gene is composed of two exons, and one of the 25 SNPs are located in the 5’-flanking region 
and 24 are in intron 1. None of the 25 SNPs are localized in the exons. I selected three SNPs 
SNP X, SNP Y and SNP Z which are located in the transcription factor binding sites; SNP X 
in the 5’-flanking region, and SNP Y and SNP Z in intron 1. To study the effect of the three 
SNPs on the SIAH2 expression, I prepared six reporter plasmids containing three regions; one 
in the 5’ flanking region (region A: between -2,151 and -571, Figure 6) and two in the intron 
1 (region B: between +10,063 and +11,152, Figure 7, and region C: between +13,956 and 
15,864, Figure 8). These constructs contained either major or minor allele of the three SNPs. 
Subsequently, a reporter gene assay was performed using these constructs (pGL3A_Major 
and pGL3A_Minor for SNP X, pGL3PB_Major and pGL3PB_Minor for SNP Y, and 
pGL3PC_Major and pGL3PC_Minor for SNP Z) in T-47D and BT-474 breast cancer cells.  
Mock vectors (pGL3-Basic or pGL3-Promoter) were used for their controls. 
As a result, I did not find any significant difference of reporter activity between 
pGL3A_Major (containing major susceptible G allele) and pGL3A_Minor (containing minor 
non susceptible T allele) in T-47D or BT-474 cells, although both constructs revealed 
markedly higher activity compared to mock vector (Figure9). This result suggested that the 5’ 
flanking region between (-2,151 and -571) contains the promoter activity and that the SNPs 
in this region may not affect the activity at least in the condition. 
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Table13. Association of rs2981579 and rs3750817 in FGFR2 in different population 
SNPs 
Minor/Major 
allele 
MAF OR P-trend Population 
rs3750817 T/C 0.49 1.22 8.47×10
-08
 Japanese 
rs3750817 T/C 0.37 0.78 8.20×10
−08
 American
34
 
rs2981579 A/G 0.47 1.20 1.77×10
-06
 Japanese 
rs2981579 A/G 0.42 1.43 3.60×10
−31
 UK
37
 
rs2981579 A/G 0.44 1.31 2.60×10
−09
 American
34
 
MAF, minor allele frequency; OR, odds ratio (calculated based on the non susceptible 
allele) except rs3750817 in American population OR, calculated based on the susceptible 
allele). 
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Figure5. Regional association plots of the locus associated with HRP 10q26 (fibroblast growth factor receptor 2 (FGFR2)). For each plot, 
_log10P of the Cochran–Armitage trend test of single-nucleotide polymorphisms (SNPs) in the genome-wide association study (GWAS) was 
plotted against relative chromosomal locations. The square and rounded signs represent imputed and genotyped SNPs, respectively. All SNPs 
are color coded as red (r
2
=0.8–1.0), orange (r2=0.6–0.8), green (r2=0.4–0.6), light blue (r2=0.4–0.6), and dark blue (r2=0.2) according to their pair 
wise r
2
 to the marker SNP. The marker SNP is represented in purple color. SNP positions followed NCBI build 36 coordinates. Estimated 
recombination rates (cM/Mb) are plotted as a blue line. 
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Figure 6: pGL3A_Major and pGL3A_Minor 
Reporter plasmid contains region A (-2.151Kb to -571 kb) of SIAH2. Plasmid pGL3A_Major 
contains major susceptible G allele and pGL3A_Minor contains minor non susceptible T 
allele of SNP X. pGL3_Mock is pGL3 basic empty vector. 
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Figure 7:pGL3PB_Major and pGL3PB_Minor 
Reporter plasmid contains region B(+10.063 to+ 11.152)of SIAH2. Plasmid pGL3PB_Major 
contains major susceptible allele and pGL3PB_Minor contains minor non susceptible allele 
of SNP Y and SNP Y1.pGL3P_Mock is pGL3 promoter empty vector. 
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Figure 8:pGL3PC_Major and pGL3PC_Minor. 
Reporter plasmid contains region C (+13.956 to +15.864) of SIAH2. Plasmid pGL3PC_Major 
contains major susceptible T allele and pGL3PB_Minor contains minor non susceptible 
Callele of SNP Z. pGL3P_Mock is pGL3 promoter empty vector.  
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A) 
 
B) 
 
Figure9. Reporter gene assay of region A contains major or minor allele of SNP X in: 
A) T47D and B) BT474 cell lines.  
Mock is pGL3 basic. 
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Interestingly, we found significant difference of reporter activity between pGL3PB_Major 
and pGL3PB_Minor in both T-47D and BT-474 cells. The activity of pGL3PB_Minor 
(containing the minor allele) was 2.9 fold higher in T-47D cells and 3.2 fold higher in BT-
474 cells than that of pGL3PB_Major (containing major allele) (Figure 10).  On the other 
hand, inconsistent reporter activity was detected between pGL3PC_Major and 
pGL3PC_Minor in T-47D and BT-474 cells. The activity of pGL3PC_Minor was slightly 
higher p value=5×10
-2 
than pGL3PC_Major in T-47D cells, but no significant difference was 
found between the two reporter plasmids in BT-474 cells p value = 3×10
-1 
(Figure 11). These 
data suggested that region B may include an enhancer region(s) for the transcriptional 
activation of SIAH2, and that minor allele of SNP Y may be associated with augmented 
expression of SIAH2 compared to the major allele. 
Therefore, I further analyzed functional roles of SNPs within region B. I identified 5 SNPs in 
region B, and found that a SNP, rs6788895, showed complete LD with SNP Y (r
2
=1) among 
the 5 SNPs.  I additionally prepared four reporter plasmids containing SNP Y; two containing 
290 bp and two containing 60 bp in region B (Figure 12 and 13). All four constructs harbored 
either susceptible minor allele G or non-susceptible major allele T of SNP Y.  The activities 
of these four plasmids were analyzed by the reporter gene assay in T47D and BT474 cells 
(Figure 14). Consistently, the reporter plasmids pGL3PB290_Minor containing non 
susceptible allele showed approximately 2.3 and 3.6 fold higher reporter activities compared 
to pGL3PB290_Major containing susceptible allele in T-47D and BT-474 cells, respectively 
(Figure 14). This result suggested that this region carries a crucial element(s) for the 
transactivation. Although the increase was lower compared to the 290 bp-region, the reporter 
plasmids pGL3PB60_Minor showed increased activity compared to pGL3PB60_Major. 
Since the 290 bp region but not the 60 bp region included another SNPY1, located 138 bp at 
a 5’ side of SNP Y. I further investigated whether this SNP also associate with the enhancer 
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A) 
 
B) 
 
Figure10. Reporter gene assay of region B containing major or minor allele of SNP Y and 
SNP Y1 in  
A) T47D and B) BT474 cell lines. Mock is pGL3promoter. 
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A) 
  
B) 
  
Figure11. Reporter gene assay of region C containing major or minor allele of SNP Z in A) 
T47D and B) BT474 cell lines. Mock is pGL3promoter 
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Figure12. B60_Major and B60_Minor 
Reporter plasmid contains region B (+10.413 to+ 10.470) of SIAH2. Plasmid B60_Major 
contains major susceptible G allele and B60_Minor contains minor non susceptible T allele 
of SNP Y. pGL3P_Mock is pGL3 promoter empty vector. 
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Figure13. B290_Major and B290_Minor 
Reporter plasmid contains region B (+10.267to + 10.556) of SIAH2. Plasmid B290_Major 
contains major susceptible alleles and B290_Minor contains minor non susceptible alleles of 
SNP Y and SNP Y1. pGL3P_Mock is pGL3 promoter empty vector. 
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A) 
 
B) 
 
Figure14. Reporter gene assay of plasmids B290 and B60 containing major or minor allele of 
SNP Y in  
A) T47D and B) BT474 cell lines. Mock is pGL3promoter. 
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activity of SIAH2. This SNP, Y1, is completely linkage to SNP Y (r
2
=1); G in SNP Y and A 
in Y1, and T in SNP Y and G in SNP Y1. I prepared additional reporter plasmids, 
pGL3PB290_Major_Mutant containing G in SNP Y and mutated allele (G) in SNP Y1, and 
pGL3PB290_Minor_Mutant containing T in SNP Y and mutated allele (T) in SNPY1 by site 
directed mutagenesis, and performed a reporter assay. As shown in Figure 15, compared to 
the variations of SNP Y, limited levels of difference in the reporter activity were observed by 
the mutation at SNP Y1. Therefore I concluded that the difference in transcriptional activity 
of the 290 bp region should be caused by the variation of SNP Y. 
To examine the effect of estrogen on SIAH2 expression, I measured the reporter activities of 
pGL3PB_Major and pGL3PB_Minor in the presence or absence of estradiol. T-47D and 
MCF7 cells transfected with pGL3PB_Major or pGL3PB_Minor were cultured in the 
presence or absence of 17β estradiol. Although slightly higher activity was detected with 
pGL3PB_Minor than pGL3PB_Major, no significant increase was observedby 17β estradiol 
(Figure 16). 
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A) 
 
B) 
 
Figure15. Reporter gene assay of plasmids B290 contains major or minor allele of Y1 and 
mutant major or mutant minor allele of in A) T47D and B) BT474 cell lines. Mock is pGL3 
promoter. 
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A) 
 
B) 
 
Figure16. Reporter gene assay of region B containing major or minor allele of SNP Y with 
17β estradiol treatment in A) MCF7 and B) T47D cell lines. Mock is pGL3 promoter, E2 is 
17β estradiol and vehicle is ethanol. 
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Chapter 5: Discussion 
In this study, I successfully identified a new genetic locus, in SIAH2, that is associated with 
HRP breast cancer in Japanese population. In addition, I validated the significant association 
of two SNPs, rs3750817 and rs2981579 in intron 2 of FGFR2 with Japanese breast cancer, 
which had been reported in various populations including Caucasians, Ashkenazi, Chinese 
and Siberians
38, 50, 51
 (Rinella et al., 2013;Boyarskikh et al., 2009;Fanale et al., 2012; Chen et 
al., 2012;Raskin et al., 2008). Although other SNPs; rs2981582, rs2420946, rs11200014, 
located in intron 2 of FGFR2 were reported to be associated with breast cancer
50
, I could not 
find any association of these SNPs with HRP breast cancer in the Japanese population. 
Moreover these SNPs showed low LD and low r
2 
with rs3750817 and rs2981579 in Japanese 
(Figure 17) indicating that these SNPs may not play a role in Japanese HRP breast cancer 
although they are found to be associated with breast cancer in other population.  The minor 
allele of rs3750817, a SNP in intron 2 of FGFR2, is a protective allele for both Japanese and 
American populations with comparable ORs (Table 13). The minor allele of rs2981579 is a 
risk allele for UK and American populations as well as Japanese. In addition, the association 
of the two SNPs in FGFR2 intron 2 with estrogen receptor positive cancer is consistent with 
earlier report
50
. Therefore FGFR2-mediated signaling should play a crucial role in HRP-
breast carcinogenesis. The intron 2 is highly conserved in various species
37
and possesses 
putative binding sites for transcription factors including FOXA1, USF1, 
http://genome.ucsc.edu/ and ER
52. Since we and others proved that intron 2 of FGFR2 is 
associated with estrogen receptor positive breast cancer, it is tempting to speculate that the 
variant(s) in the ER-binding element is a causative SNP. Nevertheless, FOXA1 and USF1 are 
also reported tobe implicated in the estrogen receptor signaling pathway
52
. FOXA1 has the 
ability to bind to the same enhancer regions of ER as a pioneer factor that facilitates the 
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association of ER with compacted DNA. In addition USF1 is considered component of a 
multi-protein complex of transcription factors that interact with ER alpha in breast cancer
53
. 
Therefore future investigation of the variants in these binding elements may clarify the roles 
of these transcription factors and reveal the precise mechanisms in HRP breast cancer 
mediated by FGFR2. 
 
 
 
Figure17. r
2
 between rs3750817, rs2981579 and 
rs2981582, rs28981579, rs2420946, rs11200014, 
rs1219648.  
 
 
In the study of SIAH2, I focused on three SNPs; SNP X, SNP Y, and SNP Z Figure 18 A&B 
that are located in transcription factors binding sites. Among the three, the variation of SNP 
Y was significantly associated with the transcriptional activity, suggesting that the variation 
may play a role as a transcriptional enhancer.  Although SNP Y, showing perfect LD with the 
marker SNP rs6788895, was significantly associated with HRP tumors, it was not associated 
with hormonal receptor negative breast cancer (Table 9). This may suggest that SIAH2 is 
involved in the pathogenesis of HRP-breast cancer but not in hormone-negative breast cancer. 
Notably, recent genetic studies showed that the SIAH2 region on chromosome 3q25.1 might 
be involved in estrogen-dependent diseases such as development of peritoneal 
leiomyomatosis and uterine fibrosis
54,55
. In addition, SIAH2 expression is up-regulated by 
estrogenand down regulated by selective estrogen receptor modulator (SERM) tamoxifen
56, 57
. 
Therefore, SIAH2 may play a crucial in the regulation of cell growth and/or cell fate in 
response to estrogen. 
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SIAH2 encodes a 324 amino acid protein that shares 68% identity with Drosophilasina and 
77% identity with SIAH1
58
.  SIAH proteins are suggested to play an important role in the 
specification of cell fate. It was reported that SIAH2 acts as an E3-ubiquitin ligase as a part of 
ubiquitin ligase-complexes and that the complexes are involved in protein degradation 
through ubiquitin-proteosome system. SIAH2 was known to induce ubiquitin-mediated 
degradation of many substrates, including proteins involved in transcriptional regulation 
(POU2AF1, PML and NCOR1), a cell surface receptor (DCC) and an anti-apoptotic protein 
(BAG1). These proteins were reported to have implication to breast cancer by different 
mechanisms
59-63
. In addition, SIAH2 protein was indicated to have an essential role in the 
hypoxic response by regulating the hypoxia-inducible factor-α64. The role of SIAH2 in human 
carcinogenesis remains controversial.  It is reported that SIAH2 has tumor suppressor effect 
by elimination of oncogenic proteins through proteasomal and kinase signaling pathways in 
leukemia
65
.  On the contrary, increased SIAH2 expression and its oncogenic role were shown 
in human neuroendocrine (NE) prostate tumor samples
66
. Additionally, nuclear accumulation 
of SIAH2 was detected in human hepatocellular carcinoma and its expression was associated 
with enhanced motility and proliferation of liver cancer cell
67
. Although previous reports 
implicated possible roles of SIAH2 in breast carcinogenesis
32,64,68,69
, the role of SIAH2 in 
breast carcinogenesis is also controversial. It was reported that SIAH2 was under-expressed 
in breast cancer and that the patients with low level of expression of SIAH2 had higher risk 
of recurrence and low chance of disease free survival with increased the aggressiveness of the 
breast cancer
70
. These data support the possible role of SIAH2 as a tumor suppressor for 
breast cancer. This view is in good agreement with the reduced reporter activity of the risk 
allele of SNP Y.  Meanwhile, SIAH2 was reported to have oncogenic effect in aggressive 
tumors associated with hypoxia such as basal-like phenotype breast cancer
71. The expression 
of SIAH2 is increased from in-situ to invasive carcinomas due to the hypoxia resulting from 
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increase of the metabolic demand as well as the demand of the oxygen supply. It was 
reported that low levels of SIAH2 were associated with resistance of breast cancer cells to 
tamoxifen, an inhibitor of estrogen receptor
32
. Considering that SIAH2 expression is regulated 
by ER, insufficient under-regulation of SIAH2 by tamoxifen may render cancer cells to 
escape from apoptosis or growth suppression. Further investigation of the SNPs in SIAH2 
may help the personalized tamoxifen treatment for patients with HRP breast cancer. 
The SNP Y was predicted to present within the transcription factor binding site of I, II and III 
transcription factor using Figure 18 A. In addition to rs73008905 was predicted to be present 
in within IV and vicinity of I transcription factors binding sites (http://genome.ucsc.edu/). 
Surprisingly, the transcription factors ER alpha, USF1 and FOXA1 are also candidate 
regulators of FGFR2 expression, and variants in intron 2 of FGFR2 are implicated in HRP 
breast cancer. Since ER alpha, FOXA1 and USF1 are involved in estrogen receptor signaling 
as described previously, variations of SNP Y and SNP Z may affect the estrogen-mediated 
SIAH2 expression. Future studies on SIAH2 may disclose the role of SIAH2 in HRP breast 
carcinogenesis. 
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Figure 18A.Position of region B include SNP Y & Y1 and transcription factors I & II & III 
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Figure 18 B. Position of region C include SNP Z and transcription factors I & IV 
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Chapter 6 Conclusion 
GWAS is a useful method to identify genetic loci or genes associated with phenotype. The 
information will be used for various health care services.  In my study, I discovered a link 
between SIAH2 and HRP breast cancer. Additionally, I successfully verified the association 
between FGFR2 and HRP breast cancer in Japanese population. Since SNP Y revealing 
significant association with the disease is located within I, II and III binding site these factors 
may also be involved in breast carcinogenesis. Since SIAH2 is involved in protein 
degradation via ubiquitin-proteosome system, altered expression of SIAH2 may affect the 
protein stability of tumor suppressor genes or oncogenes associated with HRP breast 
carcinogenesis. Therefore, further analysis of SIAH2 function in human carcinogenesis may 
be useful for the development of new therapeutic or preventive approaches to breast cancer. 
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